Avantor (AVTR) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business overview and market positioning

• Operates in two segments: lab (two-thirds of revenue) and production/bioscience (one-third of revenue, half of profitability), serving biopharma, healthcare, diagnostics, and advanced tech markets.

• Holds leading market positions in lab and bioprocessing, with over 2,500 on-site service associates and strong customer access.

• Over 85% of revenue is consumables-driven and highly recurring, with a specification-driven model and 90% of products self-manufactured.

• Avantor specified into 85% of top 20 biologics in 2024, targeting 90% of top 50 by 2030, including all top 5 blockbusters.

• Generates strong free cash flow due to a capital-light model and disciplined working capital management, with free cash flow conversion exceeding 100% YTD 2024.

Strategic initiatives and innovation

• New operating model launched in 2023 and transformed in 2024, aligning segments with customer needs, driving focus, and leading to share gains and new product launches.

• Divested Clinical Services assets to enhance segment focus and unlock cost savings.

• Cost transformation program targets over $300 million in savings and EBITDA run rate by end of 2026, with $150 million annual gross cost savings at YE 2024 and $75 million targeted for 2024.

• Investments in digital offerings, automation, and supply chain resiliency to enhance customer experience and operational agility.

• Enhanced offerings in bioscience production include integrated systems, emerging modality solutions, and customized products for next-gen medical applications.

Financial performance and outlook

• Projected 2024 revenue between $6.8B and $7.0B, with bioprocessing outperforming expectations and order rates improving each quarter.

• Laboratory solutions returned to growth in Q3 2024; bioprocessing growth expected at mid- to high-single digits in Q4 2024, providing momentum for 2025.

• Long-term financial targets: mid-single-digit organic revenue growth, 50–100 bps annual EBITDA margin expansion, double-digit adjusted EPS growth, and 90%+ free cash flow conversion.

• Over $2.0B net debt reduction achieved in 2023 and 2024, with leverage expected to reach or fall below 3.4x by year-end and interest expense down by ~$65M in FY 2024.

• Capital allocation will balance debt reduction, M&A, and potential shareholder returns, with near-term focus on deleveraging to below 3.0x adjusted net leverage.